Journalist Hunt

Resources ▾

Journalist DatabaseFor JournalistsPricing
LoginSign up

Derrick Miyao - Journalist Profile | Connect with top journalists

View 's journalist industries, journalist types, location, and media outlets. Use Journalist Hunt to get connected with top journalists in seconds.

Get connected with journalists today
Vice President Molecular Foundry, deepcure.ai

Derrick Miyao

Verified

Vice President Molecular Foundry, deepcure.ai

San Diego

Beats

Primary beats

u.s.Technology

Secondary beats

Women's educationInnovationRussiaBiotechnologyWorld AffairsPlanetary ScienceHigher EducationClimateCollege RecruitingNonprofitsAgriTechCryptocurrencyBlogging and writingNew Technologies

Biography

Final Covers

Transportation , History, Technology , Northern California, Politics, Urban Development

Doesn’t Cover

Journalist Type

other journalists

Seniority Positions

Vice President Molecular Foundry

Industries

Research

Medium Formats

deepcure.ai

Content

Total articles 368

  • Available on paid plans

    iPhone Users: How to send all unknown callers straight to Voicemail in 4 simple steps

    By Derrick Miyao

    Dec. 10, 2020

  • Available on paid plans

    Samsung is repairing smartphones free of charge for first responders

    By Derrick Miyao

    Apr. 23, 2020

  • Available on paid plans

    iPhone Users: How to send all unknown callers straight to Voicemail in 4 simple steps

    By Derrick Miyao

    Dec. 10, 2020

As seen in

Androidguys

Company Info

deepcure.ai

DeepCure is a biotechnology company founded in 2018 by researchers from the MIT Media Lab, based in Boston. The company focuses on small-molecule drug discovery, utilizing Artificial Intelligence (AI) to enhance pharmaceutical development. DeepCure aims to deliver better drugs more quickly and affordably by addressing challenging drug targets that traditional methods struggle to tackle. The company's core service is its AI platform, which accurately searches through a vast chemical space. This platform employs deep learning algorithms and a proprietary database of over one trillion chemistries to identify novel drug candidates. DeepCure also innovates in chemical synthesis with its Inspired Chemistry platform, capable of automating complex workflows, including the production of nirmatrelvir, the active ingredient in Paxlovid. One of DeepCure's notable drug candidates is DC-9476, a selective Brd4 BD2 inhibitor showing promise in preclinical models for autoimmune diseases like rheumatoid arthritis. The company collaborates with institutions such as the Leeds Institute of Rheumatic and Musculoskeletal Medicine to further test this candidate and is actively seeking partnerships for new small molecule discovery projects.

, ,

Founded: 2018


Journalist Hunt

Email us

contact@journalisthunt.com
Terms and ConditionsRefund PolicyPrivacy Policy

Copywright © 2025, Journalist Hunt. All right reserved